selegiline has been researched along with pioglitazone in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chapman, H; Crook, B; Hows, ME; Medhurst, AD; Quinn, LP; Upton, N; Vidgeon-Hart, M; Virley, DJ | 1 |
1 review(s) available for selegiline and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for selegiline and pioglitazone
| Article | Year |
|---|---|
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Medical Futility; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pioglitazone; Selegiline; Thiazolidinediones; Treatment Outcome | 2015 |
3 other study(ies) available for selegiline and pioglitazone
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics | 2015 |
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Hypoglycemic Agents; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; MPTP Poisoning; Nerve Degeneration; Neuroglia; Pioglitazone; Postural Balance; PPAR gamma; Psychomotor Performance; Selegiline; Serotonin; Substantia Nigra; Thiazolidinediones | 2008 |